FEops HEARTguideTM vs Tempus ECG-AF
AI Verdict
Choose FEops HEARTguideTM if…
Choose FEops HEARTguideTM if you require precise, patient-specific pre-procedural planning for structural heart interventions like TAVI or LAAO. This tool is ideal for optimizing device sizing and positioning through predictive simulations and detailed anatomical insights, ensuring a tailored approach to complex cardiac procedures.
View FEops HEARTguideTM →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your goal is to proactively identify older patients at elevated risk of developing new-onset atrial fibrillation within the next year. This AI-based algorithm is best suited for screening patients aged 65 or older without existing AF, pacemakers, or recent cardiac surgery, enabling earlier intervention and follow-up based on 12-lead ECG analysis.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | FEops HEARTguideTM | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Cloud-based | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FEops HEARTguideTMFEops HEARTguide offers a dedicated, interactive cloud-based platform with 2D and 3D viewers, providing clinicians with direct control and detailed analysis capabilities for complex procedural planning. In contrast, Tempus ECG-AF operates primarily as a background algorithm without a dedicated user interface, integrating into existing systems and returning results via APIs or file exchanges.
Clinical Value
FEops HEARTguideTMFEops HEARTguide provides predictive simulations and anatomical insights that directly optimize device sizing and positioning for complex structural heart interventions, leading to demonstrated reductions in device usage, repositionings, and procedural time, and higher procedural success rates. While Tempus ECG-AF offers valuable early risk stratification for AF, FEops HEARTguide's impact on immediate procedural outcomes for high-risk interventions is arguably more direct and significant on a per-patient basis.
Pricing & Value
Tempus ECG-AFTempus ECG-AF offers greater pricing transparency and a clearer path to value realization for healthcare providers due to its established CMS reimbursement codes (CPT 0764T and CPT 0765T) and publicly available Medicare rates. FEops HEARTguide, while offering a service-based model, does not publicly disclose pricing or reimbursement details, requiring direct contact for information.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering Business Associate Agreements (BAAs). FEops HEARTguide is cloud-based with a DICOM interface, while Tempus ECG-AF is a software solution compatible with major ECG systems and integrates with EHRs, indicating robust capabilities for integration into diverse healthcare environments.
Innovation
FEops HEARTguideTMFEops HEARTguide stands out for its pioneering use of digital twin technology combined with AI for personalized predictive simulation in structural heart procedure planning, offering unprecedented insights into device-anatomy interaction pre-operatively. This approach represents a more transformative and complex application of AI in personalized medicine compared to Tempus ECG-AF's AI-based algorithm for AF risk prediction.
Support & Docs
TieBoth companies provide contact information for support via email, and FEops HEARTguide also mentions the availability of training slide decks and a documentation page. However, neither tool provides extensive public details regarding the breadth, depth, or specific channels of their support and documentation offerings to clearly differentiate them.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | FEops HEARTguideTM | Tempus ECG-AF |
|---|---|---|
| Primary Function | Cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical insights to optimize device sizing and positioning for interventions like TAVI and LAAO. | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Key Technology/Methodology | Predictive simulation technology for device-anatomy interaction; AI-based anatomical measurements from CT scans; digital twin platform. | AI-based algorithm for 12-lead ECG analysis; trained on over 1.5 million ECGs from over 500,000 patients. |
| Target Medical Specialties | Cardiology, Cardiothoracic Surgery, Radiology | Cardiology, Geriatrics, Internal Medicine |
| Input Data Type | CT scans (DICOM interface) | 12-lead ECG recordings |
| Target Patient Population/Condition | Patients undergoing structural heart procedures like TAVI and LAAO. | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, at risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
Videos
Demos, reviews, and walkthroughs featuring FEops HEARTguideTM and Tempus ECG-AF.